Unequal Premarket Treatment Sometimes Valid, CDRH Ombudsman Says
This article was originally published in The Gray Sheet
Device manufacturers with similar products are not always treated equally in the premarket review process, but there is usually a legitimate reason for the discrepancies, CDRH Ombudsman Les Weinstein said
You may also be interested in...
An FDA dispute resolution body all but halted Cardima's chances to turn around the fortunes of its Revelation Tx microcatheter NavAblator ablation system April 19, voting 5-0 not to recommend approval of the product
CDRH's ombudsman says more manufacturer appeals of decisions made by the device center's evaluation office are causing longer resolution times for many complaints and disputes filed with the center
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.